Last updated: June 1, 2026
Executive summary
- Ameluz (aminolevulinic acid HCl) 78 mg/g gel is marketed in the EU by Biofrontera Pharma and distributed under its commercial network.
- The manufacturing supply chain is centered on Biofrontera’s controlled production and/or contract manufacturing for gel drug product and bulk in its European facilities, with packaging and release handled by qualified sites in the EU.
- For procurement and sourcing, the relevant “supplier” set is: (1) marketing authorization holder (MAH), (2) drug substance (bulk aminolevulinic acid) suppliers, (3) drug product gel manufacturers, (4) packaging and release sites, and (5) distribution partners. These are typically the parties named in EU/US labeling, regulatory submissions, and official manufacturing declarations.
Who supplies Ameluz (Biofrontera Pharma) and how is it sourced?
Quick answer (supplier roles)
- MAH / commercial supplier (EU): Biofrontera Pharma.
- Manufacturing and release: Qualified EU manufacturing sites producing the amine-levulinic acid gel (78 mg/g) and handling fill-finish, packaging, and batch release.
- Distribution: MAH-directed distribution and logistics partners for country-level commercialization.
What is the supplier structure for Ameluz gel?
Ameluz is a topical prescription gel (78 mg/g). In regulated supply chains, “supplier” usually breaks down into:
-
Marketing authorization holder (MAH)
Sets labeling, holds regulatory responsibility, and contracts manufacturing/release.
-
Drug product manufacturer (gel)
Produces the finished-goods gel and performs packaging, labeling, and release.
-
Drug substance (bulk) suppliers
Provide aminolevulinic acid HCl (or immediate precursors where permitted) to the gel manufacturer.
-
Contract packaging / logistics
Handles unit packaging, secondary packaging, and warehouse distribution.
What companies manufacture Ameluz (aminolevulinic acid HCl gel 78 mg/g)?
Quick answer
- The manufacturing chain for Ameluz is governed by Biofrontera Pharma’s controlled network of EU-qualified production sites for gel drug product, with packaging and batch release performed at associated qualified facilities under GMP.
Which manufacturing sites typically appear on Ameluz documentation?
For topical gel products, the sites named in regulatory and labeling ecosystems usually include:
- Drug product manufacturing site for the gel base and filling.
- Packaging and release site for finished-dose units.
- Quality control (QC) and batch testing sites (often integrated with manufacturing or located in the same GMP network).
What drug substance suppliers provide aminolevulinic acid HCl for Ameluz?
Quick answer
- Aminolevulinic acid HCl bulk sourcing is handled by qualified chemical suppliers through the MAH’s procurement and qualification framework.
How are drug substance suppliers contracted for aminolevulinic acid?
In practice for specialty topical drugs:
- MAH qualifies API suppliers (or bulk intermediate suppliers) for GMP compliance, CoA traceability, and impurity specs.
- Supply agreements cover annual volumes, change-control, and regulatory reporting requirements.
Where is Ameluz distributed and who are the logistics partners?
Quick answer
- Ameluz distribution is executed through MAH-led networks and country-level wholesalers in the EU.
How to identify the distribution “suppliers” in practice
The most operational view typically comes from:
- Country wholesalers listed on channel inventories
- Tender and hospital procurement channels referencing MAH-branded packaging
- Distribution subsidiaries or logistics subcontractors named in MAH supply documentation
What is the Orange Book status of Ameluz and does it change “supplier” mapping?
Ameluz is a topical drug product; US exclusivity and compendial listing would drive generic supplier entry risk, but it does not directly map manufacturing “suppliers” unless FDA labeling and inspections document them.
Key point: supplier mapping for Ameluz is primarily driven by EU GMP manufacturing declarations rather than US Orange Book listings.
Which generic or parallel product risks affect Ameluz sourcing?
Quick answer
- Supplier risk typically emerges from: (1) drug substance supply constraints, (2) drug product batch release delays, and (3) country-level parallel distribution (EU channel variation), rather than from direct “generic” competition unless an authorized generic enters.
What to monitor for supply continuity
- Bulk API continuity for aminolevulinic acid HCl
- Shelf-life and stability through the chain of custody
- Batch release lead times at the gel fill-finish and release site
Comparative: How does Ameluz’s supply chain compare with similar topical ALA therapies?
Topical aminolevulinic acid products share a common supply pattern:
- API procurement for aminolevulinic acid HCl
- gel formulation and fill-finish under GMP
- packaging and country distribution via MAH and wholesalers
Commercial implication: procurement leverage often depends more on API qualification and fill-finish capacity than on formulation differentiation.
Key takeaways
- Biofrontera Pharma is the controlling commercial and regulatory party for Ameluz in the EU.
- “Suppliers” for Ameluz in the real world are best treated as (a) MAH, (b) drug product manufacturing/release sites, (c) aminolevulinic acid HCl drug substance suppliers, and (d) distribution/wholesaling partners.
- Supply continuity risk concentrates in API availability and batch release capacity for the gel drug product.
FAQs
-
Who is the marketing authorization holder for Ameluz in the EU?
Biofrontera Pharma.
-
Is Ameluz manufactured by the MAH or by contract manufacturers?
It is produced through Biofrontera’s qualified manufacturing network, which may include contract manufacturing for gel drug product and packaging under GMP.
-
What supply chain component is most likely to constrain Ameluz availability?
Aminolevulinic acid HCl bulk supply and/or drug product batch release capacity for the gel.
-
Do parallel trade routes change who supplies Ameluz to hospitals?
They can change the channel wholesaler, while the MAH-controlled manufacturing and labeling remain the reference point.
-
Can generic Ameluz entry materially change supplier mapping?
It changes pricing and distribution, but supplier mapping for the branded product remains tied to MAH-controlled manufacturing until a true authorized generic or alternative source displaces supply.
References
- European Medicines Agency (EMA). Ameluz (aminolevulinic acid) product information and regulatory documents.
- European Commission. Community Register of orphan/central authorizations and associated product records (as applicable to Ameluz).
- Biofrontera Pharma. Ameluz prescribing information and product materials (labeling and SmPC references).
